Therapy with monoclonal antibodies. II. The contribution of Fcγ receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function

Journal of Immunology

Volumn 161, Issue 8, 1998, Pages 3862-3869

  Isaacs, John D ^a,d   Greenwood, Judith ^b,d   Waldmann, Herman ^c,d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b Peptide Therapeutics   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CHIMERIC ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; FC RECEPTOR; GLUTAMIC ACID; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G4; LEUCINE; OKT 8; PHENYLALANINE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECEPTOR BINDING; THYMECTOMY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN ENGINEERING; RATS; RECEPTORS, IGG; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032532012     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Dyer, M. J. S., G. Hale, F. G. J. Hayhoe, and H. Waldmann. 1989. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotope. Blood 73:1431.
2. Cobbold, S. P., S. Qin, L. Y. W. Leong, G. Martin, and H. Waldmann H. 1992. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129:165.
3. Neuberger, M. S., G. T. Williams, and R. O. Fox. 1984. Recombinant antibodies possessing novel effector functions. Nature 312:604.
4. Bruggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351.
5. Bruggemann, M. C., C. Teale, M. R. Clark, C. Bindon, and H. Waldmann. 1989. A match set of rat/mouse chimeric antibodies: idenfication and biological properties of rat H chain constant regions μ, γ1, γ2a, γ2b, γ2c, ε, and α. J. Immunol. 142:3145.
6. Reichmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323.
7. Alters, S. E., K. Sakai, L. Steinmann, and V. Oi. 1990. Mechanisms of anti-CD4-mediated depletion and immunotherapy: a study using a set of chimeric anti-CD4 antibodies. J. Immunol. 144:4587.
8. Bindon, C. I., G. Hale, and H. Waldmann. 1988. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. 18:1507.
9. Michaelsen, T. E., P. Garred, and A. Aase. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21:11.
10. Greenwood, J., M. Clark, and H. Waldmann. 1993. Structural motifs involved in human IgG antibody effector functoins. Eur. J. Immunol. 23:1098.
11. Isaacs, J. D., M. R. Clark, J. Greenwood, and H. Waldmann. 1992. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148:3062.
12. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332:738.
13. Duncan, A. R., J. M. Woof, L. J. Partridge, D. R. Burton, and G. Winter. 1988. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332:563.
14. Cobbold, S. P., G. Martin, and H. Waldmann. 1990. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur. J. Immunol. 20:2747.
15. Qin, S., M. Wise, S. P. Cobbold, L. Leong, Y.-C. Kong, J. Parnes, and H. Waldmann. 1990. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur. J. Immunol. 20:2737.
16. Tomonari, K. 1988. Human monoclonal antibodies. Immunol. Today 9:113.
17. Monaco, A., M. Wood, and P. S. Russel. 1966. Studies on heterologous anti-lymphocyte serum in mice. II. Effect on the immune response. J. Immunol. 96:229.
18. Pepys, M. 1972. Role of complement in induction of the allergic response. Nat. New Biol. 237:157.
19. Chappel, M. S., D. E. Isenman, M. Everett, Y. Xu, K. J. Dorrington, and M. H. Klein. 1991. Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci. USA 88:9036.
20. Wawrzynczak, E. J., S. Denham, G. D. Parnell, A. J. Cumber, P. T. Jones, and G. Winter. 1992. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting C1q and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse. Mol. Immunol. 29:221.
21. H2 domain of IgG for mouse FcγRII. Mol. Immunol. 29:53.
22. Bindon, C. I., G. Hale, M. Bruggemann, and H. Waldmann. 1988. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168:127.
23. H2 domain. J. Exp. Med. 173:1025.
24. H2 domain and is modulated by the hinge region. J. Exp. Med. 173:1483.
25. Oi, V. T., T. M. Vuong, R. Hardy, J. Reidler, J. Dangl, L. A. Herzenberg, and L. Stryer. 1984. Correlation between segmental flexibility and effector function of antibodies. Nature 307:136.
26. Clark, M. R. 1997. IgG effector mechanisms. Chem. Immunol. 65:88.
27. Ravetch, J. V., and J.-P. Kinet. 1991. Fc receptors. Annu. Rev. Immunol. 9:457.
28. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding. Immunology 86:319.
29. Shopes, B., M. Weetal, D. Holowaka, and B. Baird. 1990. Recombinant human IgG1-murine IgE chimeric immunoglobulin: construction, expression, and binding to human Fcγ receptors. J. Immunol. 145:3842.
30. Sarmay, G., R. Jefferis, E. Klein, M. Benzcur, and J. Gergely. 1985. Mapping the functional topography of Fc with monoclonal antibodies: localisation of epitopes interacting with binding sites of Fc receptor on human K cells. Eur. J. Immunol. 15:1037.
31. Shopes, B. 1992. A genetically engineered human IgG mutant with enhanced cytolytic activity. J. Immunol. 148:2918.
32. Greenwood, J., S. D. Gorman, E. G. Routledge, I. S. Lloyd, and H. Waldmann. 1994. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Ther. Immunol. 1:247.
33. Smith, R. I. F., M. J. Coloma, and S. L. Morrison. 1995. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated lysis by IgG4. J. Immunol. 154:2226.
34. Qin, S., S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259:974.
35. Bolt, S., E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, and H. Waldmann. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23:403.
36. Routledge, E. G., M. E. Falconer, H. Pope, I. S. Lloyd, and H. Waldmann. 1995. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60:847.
37. Isaacs, J. D., and H. Waldmann. 1994. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic antibodies. Ther. Immunol. 1:303.
38. Isaacs, J. D., R. A. Watts, B. L. Hazleman, G. Hale, M. T. Keogan, S. P. Cobbold, and H. Waldmann. 1992. Humanised monoclonal antibody for rheumatoid arthritis. Lancet 340:748.
39. Isaacs, J. D., M. Wing, J. D. Greenwood, B. L. Hazleman, G. Hale, and H. Waldmann. 1996. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106:427.